Moleculin Biotech Highlights Annamycin’s AML Treatment Potential

Moleculin Biotech ( (MBRX) ) just unveiled an update.

Moleculin Biotech has released the transcript of its recent Virtual Acute Myeloid Leukemia KOL event, highlighting insights from experts on Annamycin, a promising treatment for relapsed or refractory AML. The event underscored Annamycin’s potential to transform AML treatment by overcoming common drug resistance and reducing cardiotoxicity. With the launch of the MIRACLE trial, Moleculin aims to address the significant unmet need for effective AML therapies.

For an in-depth examination of MBRX stock, go to TipRanks’ Stock Analysis page.